Novo Nordisk's pricing tactics from the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who may have accused the company of cost gouging, pointing out the stark contrast in between U.S. rates and those in Europe and copyright.Scientific studies of Rybelsus and copyright have demonstrated that both of those drugs are productive